CXCL8 and esophageal cancer: Collectively, these data indicate that radiotherapy might be beneficial by decreasing IL-8 levels during and at the end of treatment for lung cancer patients and for esophageal cancer patients during treatment, suggesting that ICBs should be administered early in the treatment or after the end of treatment but not later, as also suggested by data from the PACIFIC trial [16].